Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature

Journal of Dermatological Case Reports

Volumn 8, Issue 1, 2014, Pages 24-28

  Attaway, Amy ^a   Mersfelder, Tracey L ^b   Vaishnav, Sakshi ^a   Baker, Joanne K ^a  

^a WESTERN MICHIGAN UNIVERSITY HOMER STRYKER MD SCHOOL OF MEDICINE   (United States)

^b FERRIS STATE UNIVERSITY   (United States)

Author keywords

Bullous pemphigoid; Dipeptidyl peptidase IV inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; CITALOPRAM; CLOBETASOL PROPIONATE; COMPLEMENT COMPONENT C3; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOCUSATE SODIUM; ELECTROLYTE; GLICLAZIDE; HEMOGLOBIN; IMMUNOGLOBULIN G; LEVOTHYROXINE; LISINOPRIL; METFORMIN; METHYLPREDNISOLONE; OXYBUTYNIN; PARACETAMOL; PREDNISONE; SIMVASTATIN; SITAGLIPTIN; VILDAGLIPTIN;

AGED; ARM WEAKNESS; ARTICLE; BLOOD CELL COUNT; BULLOUS PEMPHIGOID; CASE REPORT; DRUG WITHDRAWAL; ERYTHEMA; FOLLOW UP; HEMATOCRIT; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; LEUKOCYTE COUNT; LIVER FUNCTION TEST; MALE; MICROSCOPY; PRURITUS; SKIN BIOPSY; THROMBOCYTE COUNT; URTICARIA;

EID: 84898801271     PISSN: None     EISSN: 18987249     Source Type: Journal    
DOI: 10.3315/jdcr.2014.1166     Document Type: Article

References (20)

1. Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007; 33: 67-77. PMID: 18094948.
2. Culton, DA. Chapter 56. Bullous Pemphigoid. In: Fitzpatrick's Dermatology in General Medicine (Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K), 8th edn. McGraw-Hill. 2012.
3. Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006; 46: 876-886. PMID: 16855072.
4. European Medical Agency. EMA monkey study report. http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000807/WC500030597. pdf. Accessed September 2, 2013.
5. Desai S, Brinker A, Swann J, Iyasu S. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med. 2010; 170: 1169-1171. PMID: 20625027.
6. Thielitz A, Ansorge S, Bank U, Tager M, Wrenger S, Gollnick H, Reinhold D. The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzyme as possible targets in the treatment of skin diseases. Front Biosci. 2008; 13: 2364-2375. PMID: 17981718.
7. Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012; 26: 249-253. PMID: 21466592.
8. Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care. 2011; 34: e133. PMID: 21788636.
9. Aouidad I, Fite C, Marinho E, Deschamps L, Crickx B, Descamps V. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol. 2013; 149: 243-245. PMID: 23426497.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245. PMID: 7249508.
11. Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, Roujeau JC, Bernard P, Guillaume JC, Ingen-Housz-Oro S, Maillard H, Pauwels C, Picard-Dahan C, Dutronc Y, Richard MA; French Study Group for Bullous Diseases. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol. 2011; 131: 637-643. PMID: 20944650.
12. Fellner MJ. Drug-induced bullous pemphigoid. Clin Dermatol. 1993; 11: 515-520. PMID: 8124641.
13. Ohnuma K, Hosono O, Dang NH, Morimoto C. Dipeptidyl peptidase in autoimmune pathophysiology. Adv Clin Chem. 2011; 53: 51-84. PMID: 21404914.
14. Forssmann U, Stoetzer C, Stephan M, Kruschinski C, Skripuletz T, Schade J, Schmiedl A, Pabst R, Wagner L, Hoffmann T, Kehlen A, Escher SE, Forssmann WG, Elsner J, von Horsten S. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol. 2008; 181: 1120-1127. PMID: 18606664.
15. Caproni M, Calzolari A, Salvatore E, Giomi B, Volpi W, D'Agata A, Santucci M, Fabbri P. Cytokine profile and supposed contribution to scarring in cicatricial pemphigoid. J Oral Pathol Med. 2003; 32: 34-40. PMID: 12558956.
16. Ameglio F, D'Auria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br J Dermatol. 1998; 138: 611-614. PMID: 9640364.
17. D'Auria L, Cordiali Fei P, Ameglio F. Cytokines and bullous pemphigoid. Eur Cytokine Netw. 1999; 10: 123-134. PMID: 10400817.
18. Giomi B, Caproni M, Calzolari A, Bianchi B, Fabbri P. Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid. J Dermatol Sci. 2002; 30: 116-128. PMID: 12413767.
19. Giacalone B, D'Auria L, Bonifati C, Ferraro C, Riccardi E, Mussi A, D'Agosto G, Cordiali-Fei P, Ameglio F. Decreased interleukin-7 and transforming growth factor-beta1 levels in blister fluids as compared to the respective serum levels in patients with bullous pemphigoid. Opposite behavior of TNF-alpha, interleukin-4 and interleukin-10. Exp Dermatol. 1998; 7: 157-161. PMID: 9758411.
20. Bastuji-Garin S, Joly P, Picard-Dahan C, Bernard P, Vaillant L, Pauwels C, Salagnac V, Lok C, Roujeau JC. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol. 1996; 132: 272-276. PMID: 8607630.